AMELY

Across TCGA pan-cancer cohorts, AMELY mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of AMELY’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where AMELY mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AMELY is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

COAD, LSCC, and LUAD are the cancer types where AMELY tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AMELY mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	IV	+0.810	<.001	11	view →
LSCC	Female	III,IV	+1.417	<.001	9	view →
LUAD	Male	II,III,IV	+0.902	<.001	9	view →
HNSC	Male	III,IV	+0.664	<.001	8	view →
PDAC	Female	All	−0.980	<.001	7	view →
OV	All	All	+0.735	.039	2	view →
CCRCC	Female	All	−0.216	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

AMELY–COAD

Open the COAD breakdown →